24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
ADHD
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
11:16
Israeli tech’s top 10 funding rounds of 2024: Wiz sets another record
08:58
Israel will "experience a 'baby boom' of innovation" in 2025, says RUNI Ventures
18:00
Vgames raises $142 million to fuel global gaming investments
17:14
Full list of Israeli startup M&As in 2024
More stories
Buzz
Most popular
Daily
Weekly
1
Four months after Intel shut it down, Ignite relaunches as an independent accelerator
2
Boomi acquires Israeli data management startup Rivery in $100M deal
3
Israel launches its first domestically built quantum computer
4
Chainalysis acquires Israeli blockchain security startup Hexagate in $60M deal
5
“I foresee one of the best decades in the history of the State of Israel”
More news
ADHD
4 stories about ADHD
“There are so few female founders; this has to be put in the past”
21.08.24
|
Ariela Karmel
Eve Mamane, Co-Founder and CRO of mental health startup Agave Health, spoke to CTech about founding her first venture, the need to normalize female founders, and why the tech industry must eliminate outdated limitations on women in leadership roles
Israeli app launches in the U.S. and Israel, helping parents of ADHD children
15.01.24
|
James Spiro
Pery uses clinical data and LLMs to provide advice and analysis for parents managing children diagnosed with attention deficit hyperactivity disorder
“There is a $5 billion opportunity in the ADHD market”
30.01.23
|
CTech
MindTension has raised a total of $2 million for its tool helping diagnose and treat optimization of ADHD and related mental health comorbidities
Teva Reaches Confidential Patent Settlement with Neos
27.12.18
|
CTech
The agreement will enable Teva to manufacture and sell a generic version of Neos’ ADHD drug Cotempla as of 2026
Please ensure Javascript is enabled for purposes of
website accessibility